From the blog I had linked to
"Further and even more interestingly the drug makers that create the VEGF-A inhibitors are running out of their patent protection (see below). The other main drug used to treat wAMD and DME is Avastin (Bevacizumab, by Roche) which is used off-label. But these drugs have an efficacy and durability issue that seems to be lessened in combination with OPT-302.(Source: here)"
1 2
Even though it will be a combo therapy, pharma companies want that patented stream of money. As the patents are ending on Eylea and Lucentis. If they get the combo patent that is a licence to print money for 10-12ish years.
From the blog I had linked to "Further and even more...
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
43.5¢ |
Change
0.025(6.10%) |
Mkt cap ! $535.5M | |||
| Open | High | Low | Value | Volume |
| 42.0¢ | 44.0¢ | 42.0¢ | $563.2K | 1.319M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 17 | 51988 | 43.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 43.5¢ | 9685 | 6 |
View Market Depth
| Last trade - 15.24pm 29/07/2024 (20 minute delay) ? |
| OPT (ASX) Chart |